Activity Report 2018
Activity Report 2018
 
 
                        
About Us
 
                        Mission:
Conducting research of excellence in the field of the life sciences, covering the entire value of R&D&i, including technology transfer and commercial exploitation of the generated scientific results.
 
                        Strategic Challenges:
- Research of excellence
- Technology Transfer
- Collaboration with RVCTI agents
- International recognition
- Training and promotion of research talent
- Attraction and retention of talent
- Communication and Outreach
- Excellence in Management
Strategy:
Commitment to specialization and excellence
 
                        Competitiveness:
- Leading infrastructures
- Human Resources
- Technical and administrative support
- Competitive salaries
- Goal-Fulfillment Incentives
 
                
                        Staff 2018
Staff 2018.12.31: 0 181
Average Age: 0 years
Permanent staff: 0%
Gender distribution
 
                         - 
                        			0 55.2% Female 
 111
- 
                         			0% Male 
 84
- 
                         			0% LISM 
 5
195 Total CIC bioGUNE Personnel
- 
                                	0 84% Research
 163
- 
                                	0 16% Administration and services
 32
Research distribution by Proffesional Category
| nº | % |  |  | ||
| Researchers | 116 | 71.2 | 55 | 61 | |
| • Principal investigators/Platform Managers | 26 | 16.0 | 7 | 19 | |
| • Posdoctoral Researches/Research Assistant | 40 | 24.5 | 17 | 23 | |
| • PhD Student | 50 | 30.7 | 31 | 19 | |
| Technicians | 47 | 28.8 | 37 | 10 | 
Research distribution by Geographic Origin
Research distribution by Geographic Origin
- 
                           	0% Spanish
 87 researchers
- 
                        	0% Rest of Europe 
 19 researchers
- 
                            0% America
 7 researchers
- 
                        	0% Asia
 3 researchers
Training
Technology transfer and innovation 2018
New Patent Applications: 0
New Collaboration Agreements: 0
New Research Contracts: 0
0 new Patents:
- CA 0
- CA 0
0 Licensing Agreement
Economic Activity: 2.326.057€
- Basque Country: 0%
- Spain: 0%
- International: 0%
8 New Patent Applications
- 0 European Patent Application
- 0 PCT Patent Application
- 0 PTO Patent Application
Funding 2018
Total 2017 R&D Budget: 0 million €
N. R&D Projects: 0
- 0 % Public Funding
- 0 % Private Funding
- Total: 0% competitive + 0% non-competitive
- 
                                0 
                                % Basque Government Departments  (Competitive + non competitive)
 6.057 K€
- 
                         		0
                         		% MINECO & MEDC (Spanish Government)
 2.533 K€
- 
                         		0
                         		% R&D Contracts, Research Services & Others
 1.376 K€
- 
                             	0 
                             	% EU & International Projects 
 1.040 K€
R&D&I good practices
R&D Policy
The CIC bioGUNE R&D policy lays on fundamental pillars of Excellent Research in biosciences and Technology Transfer. Our activities are devoted to generation of knowledge and transfer of technologies to society and centered in specialization and excellence.
Our R&D activities follow central aspects like:
- High impact of research activities focused on ameliorating wealth of society and framed in the strategic research initiative devoted to the development of the Basque Country
- Creation and education of young scientific talent and promote career path to fulfill personal and professional development of talent
- Institutional cooperation at local, national and international level
- Internationalization and visibility of Center's activities
- Promote the knowledge transfer to society and contribute to the economic development and competitiveness of biomedicine and biotechnology industry in the Basque Country
- Insure diffusion and outreach of scientific knowledge to the society and industry
- Effective and transparent management of resources to fulfill funding agencies expectation and priorities in the Basque Country.
Se ha realizado una auditoría basada en procesos y enfocada a los aspectos significativos, riesgos, objetivos, de acuerdo con la norma de referencia. La auditoría se ha realizado por muestreo y con base a la información disponible en el momento de la auditoría. Los métodos utilizados han sido entrevistas, observación de evidencias, y revisión de la documentación y registros.
El equipo auditor considera que se han cumplido los objetivos de la auditoría y la organización ha establecido y mantenido su sistema de gestión de acuerdo a los requisitos de la norma y demuestra la capacidad del sistema para cumplir eficazmente con los requisitos del producto/servicio para el alcance, objetivos y pollitica de la organización.
 
                                        Singular Projects
Strategic Plan: Bioinformatics
Group Leader Recruitments
New Projects H2020
Scientific Output
Publications
Citations
First Quartile Q1
First Decil D1
IF > 10
Highlights
CIC bioGUNE researchers publish more than 150 publications. 17% of them have an Impact Factor above 10. The average IF in 2018 reaches 7,8.
Competitive funding at CIC bioGUNE reaches 66% of total funding.
CIC bioGUNE obtains one new ERC Advanced Grant (RECGLYCANMR) in 2018.
Two new research groups (Computational Biology and Integrative Genomics) join CIC bioGUNE.
CIC bioGUNE is recognized within the top 100 NPO/NGO Institutions worldwide, according to Nature Index.
The NMR facility of CIC bioGUNE is recognized as singular scientific infrastructure (ICTS) in Spain.
CIC bioGUNE obtains the UNE 166002 Quality Accreditation.
CIC bioGUNE and University of Deusto sign a formal agreement to foster training and research on health sciences.
The Scientific Advisory Board of CIC bioGUNE, including Nobel Laureate Richard Henderson, visits our premises for the corresponding evaluation, which is highly positive.
Scientific Highlights
 
                     
                        Cofactors influence the biological properties of infectious recombinant prions
Fernandez-Borges, N;Di Bari, MA; Erana, H; Sanchez-Martin, M; Pirisinu, L; Parra, B; Elezgarai, SR; Vanni, I; Lopez-Moreno, R; Vaccari, G; Venegas, V; Charco, JM; Gil, D; Harrathi, C; D'Agostino, C; Agrimi, U; Mayoral, T; Requena, JR; Nonno, R; Castilla, J.
Acta neuropathologica. Volume / Issue / Pages:135(2):179-199. DOi: 10.1007/s00401-017-1782-y
 
                         
                         Essentials of extracellular vesicles: posters on basic and clinical aspects of extracellular vesicles
Nieuwland, R; Falcon-Perez, JM; Soekmadji, C; Boilard, E; Carter, D; Buzas, EI.
Journal of extracellular vesicles. Volume / Issue / Pages:7(1):1548234-.DOi: 10.1080/20013078.2018.1548234
Editorial Activity
-                         	
                        		  
- 
                            	Joaquín Castilla
 Advisory Board
-                         		
                        		  
- 
                            	Juan Anguita
 Advisory Board
-                         	
                        		  
- 
                            	Malu Martínez Chantar
 Editor Board
- 
                        		  
- 
                        		Óscar Millet
 Associate Editor
 
                    - 
                            	  
- 
                            	Óscar Millet
 Editor Board
- 
                            	  
- 
                            	Juan M. Falcón
 Review Editor
- 
                            	  
- 
                            	Rosa Barrio
 Review Editor
- 
                            	  
- 
                            	Juan Anguita
 Review Editor
- 
                            	  
- 
                            	Juan Anguita
 Review Editor
 
                    - 
                        	  
- 
                        	Juan Anguita
 Editor Board
- 
                            	  
- 
                            	Rosa Barrio
 Editor Board
Nature Index

Scientific Programmes
Metabolism and Cell Signaling in Disease
- Personalized medicine
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Liver Diseases
- Rare Diseases
- Biomarkers for Diagnosis
- Biomarkers for Prognosis
- Drug Design and Discovery
Molecular Recognition and Host-Pathogen
- Rare Diseases
- Homeostasis
- Viral Infections
- Bacterial Infections
- Prion Disease
- Tick-Borne Disease
- Immune Response
- Drug Design and Discovery
Platforms
- NMR Spectroscopy
- Macromolecular Crystallography
- Electron Microscopy
- Genome Analysis
- Proteomics
- Metabolomics
- Animal Facility
Metabolism and Cell Signaling in Disease
- Personalized medicine
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Liver Diseases
- Rare Diseases
- Biomarkers for Diagnosis
- Biomarkers for Prognosis
- Drug Design and Discovery

Molecular Recognition and Host-Pathogen
- Rare Diseases
- Homeostasis
- Viral Infections
- Bacterial Infections
- Prion Disease
- Tick-Borne Disease
- Immune Response
- Drug Design and Discovery
Technological Platforms
- NMR Spectroscopy
- Macromolecular Crystallography
- Electron Microscopy
- Genome Analysis
- Proteomics
- Metabolomics
- Animal Facility
Generation of 
      knowledge
    
    Technology 
      transfer
    Commercialization of 
      results
    Scientific Programmes
     
Research lines
    
    Cancer
Metabolic diseases
Infectious disease
Rare disease
The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry and Biomedicine, with emphasis on Structural, Molecular and Cell Biology. An integrative Bioinfomatic Program extrapolate relevant conclusion from basic science.
Scientific Programmes
     
Metabolism & Cell Signaling in Disease
    
    Brain

Breast

Colon

Liver

Prostate

- Target discovery and evaluation of their therapeutic potential
- Cancer and more: Identification of biomarkers with potential diagnostic value
- Novel therapies against rare diseases
- The molecular basis of fibrosis
- Nonalcoholic steatohepatitis
The Research Programmes
     
Molecular Recognition &  Host-Pathogen Interactions
    
    Parasites

Vaccines

Antibiotics

Membrane remodelling

Animal and plant viruses

- Bacterial and Viral Infections: Vaccines for human and animal health
- Mechanisms of membrane remodelling during microbial invasion and propagation
- Plant vaccines and transgenics
- Antibiotics research and molecular characterization
The Research Programmes
     
Technology Platforms
    
    Genome Analysis Platform
Proteomics Platform
Metabolomics Platform
Animal Facility
Antibodies Production
Drug Repositioning & Discovery
Nuclear Magnetic Resonance
Macromolecular Crystallography
Electron Microscopy Platform
 
     
     
     
     
    Collaboration Models
Services
R&D Collaborations
Consulting
Theses
Infraestructuras Científicas y
Técnicas Singulares (ICTs)
    
    CIC bioGUNE es el nuevo Laboratorio de RMN de Euskadi (LRE), ICTs de RMN




Convenio Universidad de Deusto


SAB Visit 2018
1st Session

- Prof. Christian Griesinger, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
- Prof. Ulrich Günther, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, UK
- Prof. Nancy Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
- Prof. Manuel Serrano, Institut de Recerca Biomédica de Barcelona‚ Spain.
- Prof. Adriano Aguzzi, Institute of Neuropathology, University Hospital of Zurich, Switzerland
- Prof. Quentin Anstee, Institute of Cellular Medicine, Newcastle University, UK
- Prof. Tom Blundell, Department of Biochemistry, Univ of Cambridge, UK
- Prof. Avelino Corma, Instit Tecnología Química, CSIC-UPV, Valencia, Spain
- Prof. Richard Henderson, MRC Lab Molecular Biology, Cambridge, UK
2nd Session

Awards and Recognitions
  
 La Real Sociedad Española de Química concede su Medalla de Oro a Jesús Jiménez Barbero.
  
  
 El Gobierno Vasco reconoce la labor desarrollada por el investigador Óscar Millet en CIC bioGUNE
 
  
  
 Alberto Fernández Tejada, Premio Joven Investigador 2018 de la Real Sociedad Española de Química.
 
  
  
 Premio ICOMA de investigación al Dr. Joaquín Castilla
  
  
 Premios al Dr. Arkaitz Carracedo
 
-  Joven Investigador Sociedad Española de Bioquímica y Biología Molecular SEBBM 
 Joven Investigador en Oncología Fundación AstraZeneca
 VII Premio Nacional de Investigación en Cáncer‚ Doctores Diz Pintado
  
  
 
 Ganeko Bernardo
Premio José Tormo SEBBM 2018
 
 Georgina Ormaza
Best PhD Thesis, GERMN 2018
Activities 2018
Activities 
Lectures








Activities 
    Conferences








Activities 
Courses/workshops/meetings
 
    
 
    
 
    
Dissemination & Outreach
Dissemination and Outreach 
Press clippings
     
    
     
    
     
    
     
    
     
    
 
    
    
    
    
    
    
    
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
Dissemination and Outreach 
We have also participated in...
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
     
    
Dissemination & Outreach 
Radio
|  |   |  | 
|  |  |  | 
|  |  |  | 
- Arkaitz Carracedo"Premio Nacional de Investigación en Cáncer Doctores Piz Pintado" y "Premio AstraZeneca"
- Joaquín Castilla "Insomnio familiar letal"
- Hasier Eraña "artículo publicado en PNAS"
- José M Mato y Marcelo Guerín "Resistencia bacteriana"
- Juan Anguita "Enfermedad de Lyme"
- José M. Mato, Luis Liz y Jesús Jiménez Barbero "Consecución de las Avanced Grant"
- José M Mato, Óscar Millet y Joaqín Castilla "Día de las enfermedades raras"
- Arkaitz Carracedo y Verónica Torrano "Congreso del Cáncer"
- José M. Mato "El valor social de la ciencia" y "OWL Metabolics"
- Retransmisión en directo desde CIC bioGUNE del programa "Hoy por Hoy Bilbao" de la cadena SER.
 
	           
	           
	           
 

 
                                 		 
                                         		 
                                      			 
                                          		 
                                              	 
                                 		 
                                         		 
                                        	 
                                     	 
                                      		 
                                          	 
                                          	 
                                			 
                                 				 
                                    			 
                                        		 
                                        			 
                                            		 
                                            		 
                                            		 
                                          			 
                                        		 
                                         
 
                                         	 
                                         
                	 
                                		 
                                	 
                                    	 
                            	








 
  
                        	 
                        	 
 
                         	 
    
                        	 
    
                        	 
     
                         	 
                        	 
 
                     		 
  
                         	 
                         	 
                        	 
  
                         	 
                        	 
                         	 
  
                        	 
                     
                         	 
   
                        	 
        
                         	 
     
                         	 
                        
                        	 
     
                        	 
  
                        	 
                    	 
                    	 
                        	 
                     	 
                             
                    	 
                             
                             
                             
                             
                    	 
                    	 
                             
                             
                    	 
                             
                    	 
                            







